The growth of this market is mainly driven by increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and increasing number of drug development initiatives.
This report segments the creatinine measurement market on the basis of type, type of sample, end user, product, and region. By type, the market is segmented into Jaffe’s kinetic method and enzymatic method. In 2018, the Jaffe’s kinetic method segment is estimated to account for the largest share of the creatinine measurement market, as it is the oldest and most conventional method for creatinine measurement in clinical samples. Additionally, the widespread availability and cost-effectiveness of kits and reagents used in Jaffe’s kinetic method is another major factor responsible for the large share of this segment.
Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206847385
The blood sample segment accounted for the largest share of the creatinine measurement market in 2017 due to the increased accuracy and low risk of contamination. This segment is also expected to witness the highest growth over the forecast period, as it is the most preferred sample type for accurate measurement of creatinine levels.
The diagnostic laboratories segment is expected to witness the highest growth over the forecast period as various market players are entering into long-term collaborations with diagnostic laboratories in order to increase their presence in the creatinine measurement market.
The growing prevalence of CKD, rising awareness about preventive healthcare, improving healthcare infrastructure, and growing focus of market players on addressing the demands in several Asian countries. Also, as developed markets are reaching saturation levels, Asia is expected to become a hotspot for creatinine kits and reagents providers, However, identification of novel renal dysfunction Biomarkers and frequently changing regulatory policies are expected to challenge market growth in the coming years.